Skip to main content
. Author manuscript; available in PMC: 2018 May 4.
Published in final edited form as: Cell Rep. 2018 Apr 17;23(3):918–929. doi: 10.1016/j.celrep.2018.03.093

Figure 5. ARID1A Loss Associates with Platinum and PARP Inhibitor Resistance in Patient Cohorts.

Figure 5

(A) Impact of ARID1A loss, determined via mutation, homozygous deletion, or loss of expression, and survival in TCGA serous ovarian cancers.

(B) Progression-free survival of relapsed, platinum-sensitive, high-grade ovarian carcinomas in a clinical trial of rucaparib, stratified based on ARID1A mutation status.

The p values are based on log-rank test. HR, hazard ratio; CI, confidence interval of survival.

See also Figure S3 and Table S5.